165 related articles for article (PubMed ID: 16712616)
1. Propylthiouracil-associated liver failure presenting as probable autoimmune hepatitis in a child with Graves' disease.
Sipe WE; Su M; Posselt A; Kim GE; Quiros JA; Rosenthal P
Pediatr Transplant; 2006 Jun; 10(4):525-8. PubMed ID: 16712616
[TBL] [Abstract][Full Text] [Related]
2. A case of autoimmune hepatitis with Graves' disease treated by propylthiouracil.
Sato I; Tsunekawa T; Shinohara Y; Nishio Y; Shimizu Y; Suzuki Y; Yoshioka S
Nagoya J Med Sci; 2011 Aug; 73(3-4):205-9. PubMed ID: 21928702
[TBL] [Abstract][Full Text] [Related]
3. Antineutrophilic cytoplasmic antibody-positive systemic vasculitis associated with propylthiouracil therapy: report of 2 children with Graves' disease.
Poomthavorn P; Mahachoklertwattana P; Tapaneya-Olarn W; Chuansumrit A; Chunharas A
J Med Assoc Thai; 2002 Nov; 85 Suppl 4():S1295-301. PubMed ID: 12549809
[TBL] [Abstract][Full Text] [Related]
4. Treatment outcome of Graves' disease in Thai children.
Somnuke PH; Pusuwan P; Likitmaskul S; Santiprabhob J; Sawathiparnich P
J Med Assoc Thai; 2007 Sep; 90(9):1815-20. PubMed ID: 17957924
[TBL] [Abstract][Full Text] [Related]
5. Prevalence and clinical significance of antineutrophil cytoplasmic antibody in Graves' patients treated with propylthiouracil.
Cin MO; Gursoy A; Morris Y; Aydintug OT; Kamel N; Gullu S
Int J Clin Pract; 2009 Feb; 63(2):299-302. PubMed ID: 19196368
[TBL] [Abstract][Full Text] [Related]
6. Prevalence of perinuclear antineutrophil cytoplasmic antibody in patients with Graves' disease treated with propylthiouracil or methimazole in Taiwan.
Huang CN; Hsu TC; Chou HH; Tsay GJ
J Formos Med Assoc; 2004 Apr; 103(4):274-9. PubMed ID: 15175822
[TBL] [Abstract][Full Text] [Related]
7. High prevalence of antineutrophil cytoplasmic antibody positivity in childhood onset Graves' disease treated with propylthiouracil.
Sato H; Hattori M; Fujieda M; Sugihara S; Inomata H; Hoshi M; Miyamoto S
J Clin Endocrinol Metab; 2000 Nov; 85(11):4270-3. PubMed ID: 11095466
[TBL] [Abstract][Full Text] [Related]
8. The effect of combination therapy with propylthiouracil and cholestyramine in the treatment of Graves' hyperthyroidism.
Tsai WC; Pei D; Wang TF; Wu DA; Li JC; Wei CL; Lee CH; Chen SP; Kuo SW
Clin Endocrinol (Oxf); 2005 May; 62(5):521-4. PubMed ID: 15853819
[TBL] [Abstract][Full Text] [Related]
9. Comparison of single daily dose of methimazole and propylthiouracil in the treatment of Graves' hyperthyroidism.
He CT; Hsieh AT; Pei D; Hung YJ; Wu LY; Yang TC; Lian WC; Huang WS; Kuo SW
Clin Endocrinol (Oxf); 2004 Jun; 60(6):676-81. PubMed ID: 15163329
[TBL] [Abstract][Full Text] [Related]
10. Treatment with propylthiouracil is associated with appearance of antineutrophil cytoplasmic antibodies in some patients with Graves' disease.
Sera N; Ashizawa K; Ando T; Abe Y; Ide A; Usa T; Tominaga T; Ejima E; Yokoyama N; Eguchi K
Thyroid; 2000 Jul; 10(7):595-9. PubMed ID: 10958312
[TBL] [Abstract][Full Text] [Related]
11. Clinical importance of antineutrophil cytoplasmic antibody positivity during propylthiouracil treatment.
Yazisiz V; Ongüt G; Terzioğlu E; Karayalçin U
Int J Clin Pract; 2010 Jan; 64(1):19-24. PubMed ID: 18284438
[TBL] [Abstract][Full Text] [Related]
12. Time interval between the last dose of propylthiouracil and I-131 therapy influences cure rates in hyperthyroidism caused by Graves' disease.
Turton DB; Silverman ED; Shakir KM
Clin Nucl Med; 1998 Dec; 23(12):810-4. PubMed ID: 9858291
[TBL] [Abstract][Full Text] [Related]
13. Gone (from the Physicians' desk reference) but not forgotten: propylthiouracil-associated hepatic failure: a call for liver test monitoring.
Primeggia J; Lewis JH
J Natl Med Assoc; 2010 Jun; 102(6):531-4. PubMed ID: 20575220
[TBL] [Abstract][Full Text] [Related]
14. The Role of Propylthiouracil in the Management of Graves' Disease in Adults: report of a meeting jointly sponsored by the American Thyroid Association and the Food and Drug Administration.
Bahn RS; Burch HS; Cooper DS; Garber JR; Greenlee CM; Klein IL; Laurberg P; McDougall IR; Rivkees SA; Ross D; Sosa JA; Stan MN
Thyroid; 2009 Jul; 19(7):673-4. PubMed ID: 19583480
[No Abstract] [Full Text] [Related]
15. Severe hepatotoxicity on beginning propylthiouracil therapy.
Lock DR; Sthoeger ZM
J Clin Gastroenterol; 1997 Jun; 24(4):267-9. PubMed ID: 9252857
[TBL] [Abstract][Full Text] [Related]
16. Graves' disease accompanied by anti-myeloperoxidase antibody-related nephropathy and autoimmune hepatitis.
Nagai T; Imamura M; Kamiya Y; Mori M
Intern Med; 2004 Jun; 43(6):516-20. PubMed ID: 15283191
[TBL] [Abstract][Full Text] [Related]
17. Recovery from pancytopaenia and liver dysfunction after administration of propylthiouracil for Graves' disease.
Kebapcilar L; Yeşil S; Bayraktar F; Saklamaz A; Demir T; Güngör O; Alacacioglu I; Cömlekçi A
N Z Med J; 2005 Aug; 118(1220):U1615. PubMed ID: 16132076
[No Abstract] [Full Text] [Related]
18. Outcome of pediatric Graves' disease after treatment with antithyroid medication and radioiodine.
Ward L; Huot C; Lambert R; Deal C; Collu R; Van Vliet G
Clin Invest Med; 1999 Aug; 22(4):132-9. PubMed ID: 10497711
[TBL] [Abstract][Full Text] [Related]
19. Propylthiouracil associated antineutrophil cytoplasmic antibodies (ANCA) in patients with childhood onset Graves' disease.
Panamonta O; Sumethkul V; Radinahmed P; Laopaiboon M; Kirdpon W
J Pediatr Endocrinol Metab; 2008 Jun; 21(6):539-43. PubMed ID: 18717240
[TBL] [Abstract][Full Text] [Related]
20. Propylthiouracil and carbimazole associated-antineutrophil cytoplasmic antibodies (ANCA) in patients with Graves' disease.
Harper L; Chin L; Daykin J; Allahabadia A; Heward J; Gough SC; Savage CO; Franklyn JA
Clin Endocrinol (Oxf); 2004 Jun; 60(6):671-5. PubMed ID: 15163328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
